Catalyst Wire Dossier Catalyst Wire Dossier
CLINICAL_TRIALS trial_result · 2023-03-02

Clinical Trial Update: A Study to Evaluate the Efficacy and Safety of Imsidolimab (ANB019) in the Treatment of Participants With Ichthyosis [Phase 2]

View source ↗

Summary

Phase 2 trial evaluating imsidolimab for ichthyosis was terminated and results have been posted.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

Drugs mentioned

  • Imsidolimab (ANB019) (imsidolimab)

Snippet

Sponsor: Vanda Pharmaceuticals | Conditions: Ichthyosis | Phase 2 | Status: TERMINATED | Results posted: 2023-03-02